Daily non-political popular news in brief.

Combination treatment stymies breast cancer growth

A combination of three different drugs that block the HER-2 receptor, a critical cellular growth signal for some breast cancers, eradicated aggressive breast tumors in mice and could point the way toward developing better treatments in patients, said researchers from the Breast Center at Baylor College of Medicine in a report that appears today in the Journal of the National Cancer Institute.

Read more »

Keywords: combination, treatment, stymies, breast, cancer, growth, stymy

« Previous | Next »

Similar news on "Combination treatment stymies breast cancer growth":

1. Growth factors given with chemotherapy associated with increased risk of blood diseases
   02-06-2007 · EurekAlert!
   Women with breast cancer who receive compounds that stimulate white blood cell production to help their bodies better tolerate chemotherapy are at an increased risk of developing a type of leukemia or a condition called myelodysplastic syndrome, according to a new study in the February 7, Journal of the National Cancer Institute. The authors note that the absolute risk of the conditions is very small, but that risk should still be taken into consideration when making treatment decisions.
   Similar news · Read more »
   
2. Study supports activity of GEMZAR in the treatment of early-stage breast cancer
   06-02-2007 · EurekAlert!
   GEMZAR (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study presented today with encouraging results in the pre-surgical treatment of breast cancer. The study was presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
   Similar news · Read more »
   
3. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
   12-13-2007 · EurekAlert!
   High-dose chemotherapy and autologous stem cell transplantation, the controversial, arduous, yet once-popular combination treatment that fell out of favor as a therapy for breast cancer, has proven not to be beneficial as an adjuvant therapy for women with node-positive disease, according to an expansive analysis conducted by researchers at the University of Texas M. D. Anderson Cancer Center.
   Similar news · Read more »
   
4. Bevacizumab found to improve survival for patients with advanced breast cancer
   12-26-2007 · EurekAlert!
   Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
   Similar news · Read more »
   
5. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
   01-31-2008 · EurekAlert!
   Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
   Similar news · Read more »
   
6. Combining therapies can improve survival for early-stage breast cancer patients
   04-03-2007 · EurekAlert!
   Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
   Similar news · Read more »
   
7. Herceptin does not increase heart failure in patients long-term
   06-03-2007 · EurekAlert!
   Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
   Similar news · Read more »
   
8. Treatment-induced growth factor causes cancer progression
   04-05-2007 · EurekAlert!
   A research team at the Vanderbilt-Ingram Cancer Center, led by Carlos Arteaga, M.D., reports in the May issue of the Journal of Clinical Investigation that radiation and chemotherapy increase circulating levels of the growth factor TGF-beta, circulating cancer cells, and tumor metastases in a mouse model of metastatic breast cancer.
   Similar news · Read more »
   
9. Analysis confirms benefits of combining trastuzumab and chemotherapy
   07-07-2007 · EurekAlert!
   A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
   Similar news · Read more »
   
10. Novel medication improves ovarian cancer treatment
    10-31-2007 · EurekAlert!
    A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anticancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.
    Similar news · Read more »